Meeting
2019 ASCO Annual Meeting
Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.
Authors
Hans-Christian Kolberg
Marienhospital, Bottrop, Germany
Hans-Christian Kolberg , Marco Colleoni , Georgia Demetriou , Patricia Xavier Santi , Hans Tesch , Yasuhiro Fujiwara , Zorica Tomasevic , Vladimir Hanes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT01901146
Citation
J Clin Oncol 37, 2019 (suppl; abstr 557)
DOI
10.1200/JCO.2019.37.15_suppl.557
Abstract #
557
Poster Bd #
49
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC).
First Author: Justin Stebbing
Poster
2017 ASCO Annual Meeting
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer.
First Author: Xavier B. Pivot
Poster
2017 ASCO Annual Meeting
Results of multicenter phase II WSG Neo-Predict trial: Predictive markers for evaluation of response to neoadjuvant paclitaxel+trastuzumab+lapatinib in HER2-positive early breast cancer.
First Author: Christian Eichler
Poster
2015 ASCO Annual Meeting
Total pathologic complete response (tpCR) and event-free survival (EFS) with subcutaneous (SC) or intravenous (IV) trastuzumab in HER2-positive early breast cancer (EBC).
First Author: Christian Jackisch